- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07287670
EncompaSSc: Utvärdering av MTX-474 hos deltagare med diffus kutan systemisk skleros (dcSSc)
En fas 2-randomiserad, dubbelblind, placebokontrollerad studie för att bedöma säkerheten och effekten av MTX-474 vid behandling av deltagare med diffust kutant systemisk skleros (dcSSc)
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Participants with dcSSc who meet the study's inclusion and exclusion criteria will be randomly assigned in a 3:2 ratio to receive MTX-474 or a matching placebo by intravenous (IV) infusion. Concomitant use of one of the approved dcSSc therapies (immunosuppressive therapy, systemic glucocorticoids or other antifibrotic agents) is permitted under certain criteria. Participants randomized to the MTX-474 arm of the study will receive an IV infusion every 4 weeks, beginning at Day 0 and ending at Week 20. The End of Treatment Visit will occur at Week 24, and a Safety Follow-Up Visit will occur at Week 28, 8 weeks after the final infusion. mRSS assessments will occur at Screening, Baseline, and at all subsequent treatment visits up to and including Week 24. Spirometry will be performed at screening and Weeks 12. HRCT will be performed at screening and week 24. DLCO will be performed at Screening. Skin biopsies will be performed at Baseline and Week 12. Participants will have blood drawn for safety assessment and to assess Ephrin receptor levels at Screening, Baseline and every 4 weeks until Week 28. Blood will be drawn for serum PK analyses relative to the first and last doses of MTX-474.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Jeffrey Bornstein, MD
- Telefonnummer: 803 (617) 936-0960
- E-post: jeffrey@mediartx.com
Studieorter
-
-
Queensland
-
Southport, Queensland, Australien, 4222
- Rekrytering
- Griffith University (Clinical Trial Unit)
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Huvudutredare:
- Gerald Tracey
-
Woolloongabba, Queensland, Australien, 4102
- Rekrytering
- Veracity Clinical Research
-
Huvudutredare:
- Lynda Spelman
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
-
Victoria
-
Heidelberg, Victoria, Australien, 3084
- Rekrytering
- Austin Health
-
Huvudutredare:
- Jessica Leung
-
Kontakt:
- Rheumatology Department
- Telefonnummer: 617-802-6568
- E-post: rheumatology@austin.org.au
-
-
-
-
-
La Tronche, Frankrike, 38700
- Har inte rekryterat ännu
- EncompaSSc site in La Tronche, France
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Montpellier, Frankrike, 34090
- Har inte rekryterat ännu
- EncompaSSc site in Montpellier, France
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Paris, Frankrike, 75014
- Har inte rekryterat ännu
- EncompaSSc site in Paris, France
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Strasbourg, Frankrike, 67000
- Har inte rekryterat ännu
- EncompaSSc site in Strasbourg, France
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Toulouse, Frankrike, 31059
- Har inte rekryterat ännu
- EncompaSSc site in Toulouse, France
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Vandœuvre-lès-Nancy, Frankrike, 54500
- Har inte rekryterat ännu
- EncompaSSc site in Vandœuvre-lès-Nancy, France
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
-
-
-
Arizona
-
Phoenix, Arizona, Förenta staterna, 85054
- Har inte rekryterat ännu
- EncompaSSc site in Phoenix, AZ
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
-
California
-
La Jolla, California, Förenta staterna, 92037
- Har inte rekryterat ännu
- EncompaSSc site in La Jolla, CA
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Loma Linda, California, Förenta staterna, 92350
- Har inte rekryterat ännu
- EncompaSSc site in Loma Linda, CA
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Los Angeles, California, Förenta staterna, 90095
- Rekrytering
- University of California Los Angeles Scleroderma Center
-
Huvudutredare:
- Elizabeth Volkmann
-
Kontakt:
- Nahal Ghanoongooi
- Telefonnummer: 617-802-6568
- E-post: nghanoongooi@mednet.ucla.edu
-
Newport Beach, California, Förenta staterna, 92663
- Rekrytering
- NewportNativeMD, Inc.
-
Huvudutredare:
- Ryan Klein
-
Kontakt:
- Jennifer Gonzolez
- Telefonnummer: 617 802 6568
- E-post: jennifer@newportnativemd.com
-
Palo Alto, California, Förenta staterna, 94304
- Har inte rekryterat ännu
- EncompaSSc site in Palo Alto, CA
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
- Rekrytering
- University of Colorado Center for Lungs/Breathing/Scleroderma Clinic
-
Kontakt:
- Chong Pedrick
- Telefonnummer: 617-802-6568
- E-post: CHONG.PEDRICK@CUANSCHUTZ.EDU
-
Huvudutredare:
- Melissa Griffith
-
-
Florida
-
Clearwater, Florida, Förenta staterna, 33765
- Rekrytering
- Clinical Research of West Florida
-
Huvudutredare:
- Rodney Daniel
-
Kontakt:
- Amber Tipker
- Telefonnummer: 617 802 6568
- E-post: atipker@crwf.com
-
Sarasota, Florida, Förenta staterna, 34239
- Rekrytering
- Sarasota Arthritis Center
-
Huvudutredare:
- Jesse Boodoo
-
Kontakt:
- Research Department
- Telefonnummer: 1-941-365-0770 ext:1052
- E-post: research@arthritiscenters.net
-
Tampa, Florida, Förenta staterna, 33606
- Rekrytering
- Clinical Research of West Florida
-
Huvudutredare:
- John Carter
-
Kontakt:
- Michelle Villela
- Telefonnummer: 617 802 6568
- E-post: mvillela@crwf.com
-
-
Kansas
-
Kansas City, Kansas, Förenta staterna, 66103
- Har inte rekryterat ännu
- EncompaSSc site in Kansas City, KS
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21205
- Rekrytering
- Johns Hopkins University
-
Huvudutredare:
- Laura Hummers
-
Kontakt:
- Gwen Leatherman
- Telefonnummer: 617 802 6568
- E-post: gleathe1@jh.edu
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02115
- Rekrytering
- Brigham and Women's Hospital
-
Kontakt:
- Joyce Shen
- Telefonnummer: 617-802-6568
- E-post: jshen0@bwh.harvard.edu
-
Huvudutredare:
- Avery LaChance
-
Boston, Massachusetts, Förenta staterna, 02118
- Rekrytering
- Boston Medical Center
-
Kontakt:
- Kimberly Finch
- Telefonnummer: 617 802 6568
- E-post: kimtobin@bu.edu
-
Huvudutredare:
- Andreea Bujor
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55455
- Har inte rekryterat ännu
- EncompaSSc site in Minneapolis, MN
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
-
New York
-
Brooklyn, New York, Förenta staterna, 11201
- Rekrytering
- NYU Langone Health
-
Huvudutredare:
- David Goddard
-
Kontakt:
- Debra London
- Telefonnummer: 617-802-6568
- E-post: Debra.London@nyulangone.org
-
-
Ohio
-
Cleveland, Ohio, Förenta staterna, 44195
- Har inte rekryterat ännu
- EncompaSSc site in Cleveland, OH
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73104
- Rekrytering
- The University of Oklahoma Health Sciences Center
-
Kontakt:
- Tiffany Moore
- Telefonnummer: 405-271-3480
- E-post: OSCTR@ouhsc.edu
-
Huvudutredare:
- Aikaterini Thanou
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19107
- Har inte rekryterat ännu
- EncompaSSc site in Philadelphia, PA
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Pittsburgh, Pennsylvania, Förenta staterna, 15219
- Rekrytering
- University of Pittsburgh Medical Center
-
Kontakt:
- UPMC
- Telefonnummer: 617-802-6568
- E-post: kal128@pitt.edu
-
Huvudutredare:
- Christina Padilla
-
-
Texas
-
Allen, Texas, Förenta staterna, 75013
- Rekrytering
- Stryde Research - DFW
-
Huvudutredare:
- John Lavery
-
Kontakt:
- Moraima Avalos
- Telefonnummer: 617-802-6568
- E-post: patients@stryderesearch.com
-
Dallas, Texas, Förenta staterna, 75246
- Rekrytering
- Baylor Scott & White Research Institute
-
Kontakt:
- Felicia Padilla
- Telefonnummer: 617-802-6568
- E-post: felicia.padilla@bswhealth.org
-
Huvudutredare:
- Susan Mathai
-
Houston, Texas, Förenta staterna, 77030
- Har inte rekryterat ännu
- EncompaSSc site in Houston, TX
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
-
-
-
-
Ancona, Italien, 60126
- Har inte rekryterat ännu
- EncompaSSc site in Ancona, Italy
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Catania, Italien, 95123
- Har inte rekryterat ännu
- EncompaSSc site in Catania, Italy
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Genoa, Italien, 16132
- Har inte rekryterat ännu
- EncompaSSc site in Genoa, Italy
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Milan, Italien, 20122
- Har inte rekryterat ännu
- EncompaSSc site in Milan, Italy
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Modena, Italien, 41124
- Har inte rekryterat ännu
- EncompaSSc site in Modena, Italy
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Roma, Italien, 00128
- Har inte rekryterat ännu
- EncompaSSc site in Roma, Italy
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
-
-
-
-
Groningen, Nederländerna, 9713 GZ
- Har inte rekryterat ännu
- EncompaSSc site in Groningen, Netherlands
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
-
-
-
-
Auckland, Nya Zeeland, 2025
- Rekrytering
- Aotearoa Clinical Trials
-
Huvudutredare:
- Mark Sapsford
-
Kontakt:
- Research Department
- Telefonnummer: 617-802-6568
- E-post: info@aotearoatrials.nz
-
Hamilton, Nya Zeeland, 3204
- Rekrytering
- Waikato Hospital
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Huvudutredare:
- Kamal Solanki
-
-
-
-
-
Bydgoszcz, Polen, 85-168
- Har inte rekryterat ännu
- EncompaSSc site in Bydgoszcz, Poland
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Nowa Sól, Polen, 67-100
- Har inte rekryterat ännu
- EncompaSSc site in Nowa Sól, Poland
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Warsaw, Polen, 00-874
- Har inte rekryterat ännu
- EncompaSSc site in Warszawa, Poland
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Warsaw, Polen, 02-507
- Har inte rekryterat ännu
- EncompaSSc site in Warszawa, Poland
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
-
-
-
-
Brasov, Rumänien, 500283
- Har inte rekryterat ännu
- EncompaSSc site in Brasov, Romania
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Bucharest, Rumänien, 030463
- Har inte rekryterat ännu
- EncompaSSc site in Bucharest, Romania
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Bucharest, Rumänien, 041303
- Har inte rekryterat ännu
- EncompaSSc site in Bucharest, Romania
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Timișoara, Rumänien, 300133
- Har inte rekryterat ännu
- EncompaSSc site in Timişoara, Romania
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
-
-
-
-
Barcelona, Spanien, 08003
- Har inte rekryterat ännu
- EncompaSSc site in Barcelona, Spain
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Barcelona, Spanien, 08025
- Har inte rekryterat ännu
- EncompaSSc site in Barcelona, Spain
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Córdoba, Spanien, 14004
- Har inte rekryterat ännu
- EncompaSSc site in Córdoba, Spain
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Málaga, Spanien, 29004
- Har inte rekryterat ännu
- EncompaSSc site in Malaga, Spain
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Valencia, Spanien, 46026
- Har inte rekryterat ännu
- EncompaSSc site in Valencia, Spain
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
-
-
-
-
Coventry, Storbritannien, CV2 2DX
- Har inte rekryterat ännu
- EncompaSSc site in Walsgrave Coventry, UK
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
Liverpool, Storbritannien, L7 8XP
- Rekrytering
- Royal Liverpool University Hospital
-
Huvudutredare:
- Marina Anderson
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
London, Storbritannien, SW8 3RN
- Har inte rekryterat ännu
- EncompaSSc site in London, UK
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617 802 6568
- E-post: EncompaSSc@mediartx.com
-
Westcliff-on-Sea, Storbritannien, SS0 0RY
- Har inte rekryterat ännu
- EncompaSSc site in Westcliff-on-Sea, UK
-
Kontakt:
- EncompaSSc contact
- Telefonnummer: 617-802-6568
- E-post: EncompaSSc@mediartx.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Diagnosis of diffuse cutaneous systemic sclerosis, classified according to 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR)
-
Participant is either:
- Within 2 years of their first non-Raynaud's symptom and their mRSS is >7; OR
- >2 and ≤5 years from their first non-Raynaud's symptom, their mRSS is between 10 and 30, they are negative for the RNA polymerase 3 autoantibody, and (1) they have never had any previous spontaneous improvement in skin thickening of ≥4 points by mRSS on exams performed by the same clinician, or (2) they were never clinically noted to have a meaningful spontaneous reduction in skin thickness if mRSS was never done; OR
- >5 and ≤10 years from their first non-Raynaud's symptom, their mRSS is between >15 and ≤25, they are negative for the RNA polymerase 3 autoantibody, and (1) they have never had any previous spontaneous improvement in skin thickening of ≥4 points by mRSS, or (2) were never clinically noted to have a meaningful spontaneous reduction in skin thickness if mRSS was never done.
-
Participant is ≥18 years of age at time of signing the ICF.
-
Able to understand the study and provide a signed, written ICF
-
Able to read and understand the language of the ICF and other study-related materials
-
Forced vital capacity (FVCpp) of ≥45 pp10
-
Have diffusing capacity of the lungs for carbon monoxide (DLCO) of ≥30 percent predicted at Screening
-
Willing and able to complete all protocol-required study visits and procedures
-
Participants of childbearing potential must have a negative serum pregnancy test at Screening.
-
All participants with reproductive potential must agree to use and follow medically approved, highly effective methods of contraception during treatment and until 5 half-lives or 125 days after the last dose, whichever is longer
Exclusion Criteria:
-
Concomitantly have another serious medical illness, which, in the opinion of the Investigator, would interfere with the participant's ability to complete the study
-
Participant is currently on immunosuppressive therapy, systemic glucocorticoids or other antifibrotic agents detailed as follows:
- Immunosuppresive agents: Cyclophosphamide (IV or oral if used in the 6 months prior to Screening), calcineurin inhibitors (if used in the 30 days prior to Screening), azathioprine (if used in the 30 days prior to Screening), Janus-kinase inhibitors (if used in the 30 days prior to Screening), rituximab (if used in the 6 months prior to Screening), tocilizumab (if used in the 60 days prior to Screening) or any other biologic Disease-Modifying Antirheumatic Drugs (DMARD, if used in the last 30 days or 3 half-lives prior to Screening, whichever is longer)
- Antifibrotic agents: nintedanib or pirfenidone (if used in the 30 days prior to Screening). Also, exclusionary if used within 3 months of Screening are tyrosine-kinase inhibitors with recognized anti-fibrotic activity (imatinib, nilotinib, etc.)
- Systemic glucocorticoids: equivalent doses of prednisone greater than 10 mg/day (≤10 mg/day allowed). Has received any pulse intramuscular (IM) or intravenous (IV) steroid within 1 month of Screening
- Other agents:
i. mycophenolate mofetil unless on a stable dose for at least 6 months prior to Screening and there are no plans to adjust the dose during the study; ii. mycophenolic acid unless on a stable dose for at least 6 months prior to Screening and there are no plans to adjust the dose during the study; iii. hydroxychloroquine unless on a stable dose for at least 3 months prior to Screening and there are no plans to adjust the dose during the study; and iv. methotrexate unless on a stable dose for at least 3 months prior to Screening and there are no plans to adjust the dose during the study.
-
Previous or planned hematopoietic stem cell or solid organ transplantation
-
Previous treatment with chimeric antigen receptor (CAR)-T/CAR-NK therapy
-
Clinically significant PAH as determined by the Investigator at, or prior to first day of dosing (Baseline)
-
Current use of PAH medication (endothelin receptor antagonists, prostacyclin analogues, soluble guanylate cyclase stimulators) excluding calcium channel blockers and phosphodiesterase-5 inhibitors
-
Pregnant or currently breastfeeding
-
Aspartate transaminase (AST) or alanine transaminase (ALT) >2.0 upper limit of normal
-
Creatinine clearance <45mL/min
-
History of myocardial infarction, angina or congestive heart failure
-
International normalized ratio >2 or partial thromboplastin time >1.5 × upper limit of normal
-
Active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
-
History of clinically significant thrombotic event within 12 months prior to Screening
-
Positive anticentromere antibody
-
Systemic sclerosis renal crisis within 12 months prior to Screening
-
Confirmed diagnosis of overlap syndrome, systemic lupus erythematosus with anti-double strand (ds)DNA antibody, rheumatoid arthritis with anti-cyclic citrullinated peptide (anti-CCP) antibody, or systemic sclerosis mimics (eosinophilic fasciitis, scleromyxedema) at the time of inclusion in the study
-
Known malignancy or history of malignancy within 5 years of Screening other than non-melanoma skin cancer and in situ cervical cancer
-
Major surgery within 8 weeks prior to Screening or planned surgery during study period
-
Unable to routinely access veins for blood draws and IV infusions
-
Currently receiving another experimental agent or participating in another clinical trial. If a participant has recently received another experimental agent, then the last dose must have been at least 5 half-lives or 30 days (whichever is longer) prior to Screening
-
History of myocardial infarction, angina or congestive heart failure
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Placebo-jämförare: Placebo
Placebo |
Placebo |
|
Experimentell: MTX-474
MTX-474 |
Dosage level: 4 mg/kg Unit dose strength: 50mg/ml MTX-474 is a human immunoglobulin G1 (IgG1) monoclonal antibody that binds the human EphrinB2 with high specificity and high affinity. MTX-474 is being developed as a therapy for patients with systemic sclerosis (SSc). |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change from baseline in Modified Rodnan Skin Score (mRSS)
Tidsram: Baseline to week 24
|
Mean change from baseline to week 24 in the modified Rodnan Skin Score, a clinician-assessed measure of skin thickness across 17 body areas. Unit of measure: Score (range 0-51) |
Baseline to week 24
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of participants with a gene signature response in skin biopsy
Tidsram: 12 weeks
|
Proportion of participants in each arm (MTX-474 and placebo) demonstrating a dcSSc gene expression signature response on skin biopsy at Week 12. Unit of Measure: Participants (%) |
12 weeks
|
|
Number of participants with clinically significant findings on physical examination, vital signs, and clinical laboratory tests
Tidsram: Baseline through end of study (week 28)
|
Number of participants with clinically significant findings on physical examination, vital signs, and clinical laboratory tests Unit of Measure: Participants (%) |
Baseline through end of study (week 28)
|
|
Number of participants with dose interruptions or treatment discontinuations due to adverse events
Tidsram: Baseline through end of study (week 28)
|
Number of participants with dose interruptions or treatment discontinuations due to adverse events Unit of Measure: Participants (%) |
Baseline through end of study (week 28)
|
|
Safety and tolerability of MTX-474 in participants with dcSSc: Number of participants with treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs)
Tidsram: Baseline through end of study (week 28)
|
Incidence, seriousness, and severity of TEAEs and TRAEs as determined by investigator assessment. Unit of measure: Participants (%) |
Baseline through end of study (week 28)
|
|
Serum concentration of MTX-474 at sparse PK time points
Tidsram: Baseline to week 28
|
Serum MTX-474 concentrations collected at predefined sparse PK time points to support population pharmacokinetic (popPK) analysis Unit of Measure: ng/mL |
Baseline to week 28
|
|
Clearance (CL) of MTX-474
Tidsram: Baseline to week 28
|
Clearance of MTX-474 calculated from serial PK sampling using noncompartmental analysis Unit of Measure: L/hour |
Baseline to week 28
|
|
Terminal elimination half-life (t½) of MTX-474
Tidsram: Baseline to week 28
|
Terminal elimination half-life of MTX-474 derived from serial PK sampling. Unit of Measure: Hours |
Baseline to week 28
|
|
Area under the plasma concentration-time curve (AUC) of MTX-474
Tidsram: Baseline to week 28
|
AUC of MTX-474 calculated from serial PK sampling using noncompartmental analysis. Unit of Measure: ng·h/mL |
Baseline to week 28
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of participants with a response on the revised American College of Rheumatology Composite Response Index in Systemic Sclerosis (rACR-CRISS)
Tidsram: Baseline to week 24
|
Proportion of participants achieving rACR-CRISS composite response Unit of Measure: Participants (%) |
Baseline to week 24
|
|
Change from baseline in Physician Global Assessment (PhGA) of disease status
Tidsram: Baseline to week 24
|
Mean change from baseline to week 24 in the physician global assessment (phGA) of disease status in each arm Unit of Measure: Units on 0-10 visual analog scale (higher score = worse disease) |
Baseline to week 24
|
|
Change from baseline in Patient Global Assessment (PtGA) of disease status
Tidsram: Baseline to week 24
|
Mean change from baseline to week 24 in the patient global assessment (PtGA) of disease status in each arm Unit of Measure: Units on 0-10 visual analog scale (higher score = worse disease) |
Baseline to week 24
|
|
Change from baseline in percent predicted forced vital capacity (FVCpp)
Tidsram: Baseline to week 24
|
Mean change from baseline to week 24 on percent predicted forced vital capacity (FVCpp) Unit of Measure: Percent predicted (%) |
Baseline to week 24
|
|
Change from baseline in quantitative interstitial lung disease (QILD) score by high-resolution computed tomography (HRCT)
Tidsram: Baseline to week 24
|
Mean change from baseline to week 24 in the QILD score by high resolution computed tomography scan (HRCT) in each arm Unit of Measure: Units on QILD score (0-100 scale; higher score = greater fibrosis) |
Baseline to week 24
|
|
Change from Baseline in free EphrinB2 levels
Tidsram: Baseline to week 24
|
Median change from baseline to Week 24 in serum free EphrinB2 levels in each treatment arm. Unit of Measure: pg/mL |
Baseline to week 24
|
|
Change from baseline in forced vital capacity (FVC) by EphrinB2 levels
Tidsram: Baseline to week 24
|
Mean change from baseline to Week 24 in FVC, analyzed by baseline EphrinB2 levels, in the subset of participants with interstitial lung disease (ILD). Unit of Measure: Percent predicted (%) |
Baseline to week 24
|
|
Proportion of participants achieving rACR-CRISS response by EphrinB2 levels
Tidsram: Up to 24 weeks
|
Proportion of participants achieving a response on the revised ACR Composite Response Index in Systemic Sclerosis (rACR-CRISS), stratified by baseline EphrinB2 levels. Unit of Measure: Participants (%) |
Up to 24 weeks
|
|
To assess the presence, titer and impact of antidrug antibodies (ADA) against MTX-474
Tidsram: Baseline to week 28
|
Samples will be collected from baseline until Week 28 to assess the rate at which antibodies develop to the study drug Unit of Measure: Titer units |
Baseline to week 28
|
|
Change from baseline in expression of total and phosphorylated EphB2, EphB3, and EphB4 receptors in skin
Tidsram: Baseline to Week 12
|
Mean change from baseline to Week 12 in total and phosphorylated EphB2, EphB3, and EphB4 receptor expression in skin biopsy samples. Unit of Measure: Relative expression units (fold change from baseline) |
Baseline to Week 12
|
|
Change from baseline in transcriptomic profile
Tidsram: Baseline to Week 12
|
Change from baseline to Week 12 in global transcriptomic profile via bulk RNA sequencing analysis of skin biopsies in each arm. Unit of Measure: Differential gene expression (log₂ fold change) |
Baseline to Week 12
|
|
Change from baseline in serum biomarkers of organ involvement
Tidsram: Baseline to weeks 12 and 24
|
Change from baseline to Weeks 12 and 24 in serum levels biomarkers, including but not limited to, ProC3 and IL-6 associated with organ involvement Unit of Measure: ng/mL (or unit per biomarker) |
Baseline to weeks 12 and 24
|
|
Change from baseline in fatigue symptoms (FACIT-Fatigue score)
Tidsram: Baseline to week 24
|
Mean change from baseline to Week 24 in fatigue symptoms as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue Scale. Unit of Measure: Units on FACIT-Fatigue scale (range 0-52; higher score = less fatigue) |
Baseline to week 24
|
|
Change from baseline in gastrointestinal (GI) symptoms (UCLA SCTC GIT 2.0 score)
Tidsram: Baseline to week 24
|
Mean change from baseline to Week 24 in GI symptom burden assessed by the UCLA SCTC GIT 2.0 questionnaire. Unit of Measure: Units on UCLA SCTC GIT 2.0 total score (range 0-3; higher score = worse symptoms) |
Baseline to week 24
|
|
Change from baseline in anxiety and depression symptoms (HADS)
Tidsram: Baseline to week 24
|
Mean change from baseline to Week 24 in symptoms of anxiety and depression measured by the HADS instrument. Unit of Measure: Units on Hospital Anxiety and Depression Scale (HADS total and subscale scores; range 0-21 per subscale; higher score = worse symptoms) |
Baseline to week 24
|
|
Change from baseline in HAQ-DI
Tidsram: Baseline to week 24
|
Mean change from Baseline in functional disability as assessed by HAQ-DI. Unit of measure: Score (0-3 scale) |
Baseline to week 24
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- MTX-474-S201
- 2025-523288-39 (EudraCT-nummer)
- 2025 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .